Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214617 · ClinicalTrials.gov registry record · Phase 4
Effect of Crestor on Lipoprotein Metabolism in Humans
A Phase 4 study, sponsored by Foundation for Atlanta Veterans Education and Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00214617 is a Phase 4 study that has completed, run by Foundation for Atlanta Veterans Education and Research. The registered enrollment target is 8 participants.
The verdict
NCT00214617, a Phase 4 study, has completed, sponsored by Foundation for Atlanta Veterans Education and Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is explained by a reduction in the production of LDL by the liver.
Interventions
- DRUG Rosuvastatin at 5 mg/day and 40 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214617
The ClinicalTrials.gov registry entry for NCT00214617 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foundation for Atlanta Veterans Education and Research, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin at 5 mg/day and 40 mg/day is the first listed.
NCT00214617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214617 about?
NCT00214617 is a clinical study titled "Effect of Crestor on Lipoprotein Metabolism in Humans". The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is exp...
What is the current status of trial NCT00214617?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2005-01. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00214617?
The interventions under investigation include: Rosuvastatin at 5 mg/day and 40 mg/day (DRUG).
Who is sponsoring clinical trial NCT00214617?
This trial is sponsored by Foundation for Atlanta Veterans Education and Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.